Abstract
BackgroundTyrosine kinase inhibitors (TKIs) targeting fms-like tyrosine kinase 3 (Flt3) such as quizartinib were specifically designed for acute myelo......
小提示:本篇文献需要登录阅读全文,点击跳转登录